Background Genetically modified pigs are a promising potential source of lung

Background Genetically modified pigs are a promising potential source of lung xenografts. of lung xenograft survival. Lungs that exhibited survival to 4 hours generally had reduced platelet activation and thrombin generation. GalTKO and the expression of hCD46, HO-1, hCD55 or hEPCR were associated with improved survival. hTBM, HLA-E, and hCD39 were associated with no significant effect on the primary outcome. Conclusion This meta-analysis of an extensive lung xenotransplantation series demonstrates that increasing the number of genetic modifications targeting known xenogeneic lung injury mechanisms is associated with incremental improvements in lung survival. While more detailed mechanistic studies are needed to explore the relationship between gene expression and pathway-specific injury, and explore why some genes apparently exhibit neutral (hTBM, HLA-E) or inconclusive (CD39) effects, GalTKO, hCD46, HO-1, hCD55, Chrysophanol-8-O-beta-D-glucopyranoside and hEPCR modifications were associated with significant lung xenograft protection. This analysis supports the hypothesis that multiple genetic modifications targeting different known mechanisms of xenograft injury will be required to optimize lung xenograft survival. Introduction Porcine lung xenografts are a promising alternative to critically scarce human allografts if innate immunologic barriers can be overcome. 1C3 Genetically modified heart, lung, kidney and islet xenografts have contributed to improved survival in pre-clinical models. 3C8 In Chrysophanol-8-O-beta-D-glucopyranoside particular, knocking out the -1,3 galactosyl transferase gene (GalTKO) prevents expression of galactose 1,3-galactose (Gal), 9,10 the primary target of pre-formed human anti-pig antibodies. 11 Transgenic expression of human proteins responsible for regulating critical complement pathways (hCD46, hCD55, hCD59) have also demonstrated efficacy Chrysophanol-8-O-beta-D-glucopyranoside in various models. 12C18 Targeting prothrombotic and inflammatory pathways (hTBM, hEPCR, hCD39, HO-1) and adhesive interactions (HLA-E) have been proposed to suppress Rabbit Polyclonal to EDG4 additional mechanisms of xenograft injury, some of which arise from interspecies molecular incompatibilities. 3,19C24 perfusion with human blood is a mechanistically informative whole-organ model of clinical pig-to-human xenotransplantation, and a platform for studying mechanisms of lung xenograft injury and testing genetic and pharmacologic interventions. 1,25 Our group has previously reported the effects of several genetic and pharmacologic interventions on lung xenograft performance during perfusion with human blood. 12,16,22,26,27 Although traditional experiments using this model have contributed to major advances in the field, with the exception of a few reports, Chrysophanol-8-O-beta-D-glucopyranoside such as the analysis of the GalTKO.hCD46 genotype by Burdorf porcine lung perfusion experiments. The purpose of the current study was to analyze Chrysophanol-8-O-beta-D-glucopyranoside this aggregate data set for trends associated with lung xenograft failure or survival among pig donors with various genetic modifications, each of which is designed to attenuate injury associated with one or more pathways known to drive acute lung xenograft injury. Here we present a meta-analysis of our xenoperfusion experience, using the context of the large data set to ask in an exploratory manner whether specific genetic modifications appear to contribute significantly to improve acute lung xenograft survival. 1 Methods Animal care and procedures were in compliance with National Institute of Health guidelines, and approved by the Institutional Animal Care and Use Committee; the Institutional Review Board approved human blood collection and use. Most genetically engineered pigs were obtained from Revivicor (Blacksburg, VA). Exceptions included some GalTKO, hCD55, and GalTKO.hCD55 transgenic animals, which were sourced from Imutran – Novartis USA or Immerge Biotherapeutics (Charlestown, MA), directly or via the National Swine Research Resource Center, and GalTKO.hCD39 pigs which were imported from St. Vincents Hospital (Sydney, Australia). The GalTKO.hCD46.HLAE pigs were produced by crossbreeding and cloning of Revivicor GalTKO.hCD46 pigs with.